In the modern hustle and bustle of life, emphasizing wellness and self-care has become more essential than ever. These practices not only rejuvenate our bodies and minds but also fortify us against the stresses of daily life.

The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off.

Sex hormones play a crucial role in the human body, influencing a wide range of physiological and psychological processes. These hormones are essential for the development and functioning of the reproductive system, but they also have significant effects on other aspects of our health and well-being.